Comments
Shares of GlaxoSmithKline Pharma and Sanofi may see pressure owing the penalty imposed by the Competition Commission of India on them for cartelisation while participating in the government tender for quadrivalent meningococcal meningitis vaccine. It imposed a penalty of ₹60.49 crore on GSK Pharma and ₹3.04 crore on Sanofi. The penalty is 3 per cent of the average turnover of these firms during the years 2008-10.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.